Multinational generic pharmaceutical company, Hikma Pharmaceuticals, and the biotech Arecor, have entered into an exclusive agreement to co-develop a new, ready-to-use injectable medicine in the U.S. through Hikma’s affiliate, Hikma Pharmaceuticals USA.   The product, which will be announced prior to launch, is being developed using Arecor’s proprietary drug formulation technology platform Arestat, which enhances the properties of approved therapeutic proteins and peptides to deliver new reformu...